Publication:
Neoadjuvan kemoterapi alan meme kanserli hastalarda serum M30 ve M65 düzeylerinin klinik ve patolojik prognostik parametrelerle ilişkisi ve prediktif değeri / Relationship of serum M30 and M65 levels with clinical andpatological prognostic parameters and predictive valuein neoadjuvan chemotherapy of breast cancer patients

Simple item page
dc.contributor.advisorTÜRK, Hacı Mehmet
dc.contributor.authorYILDIZ, Rabia Sevda
dc.date.accessioned2020-08-17T06:08:51Z
dc.date.available2020-08-17T06:08:51Z
dc.date.issued2017
dc.descriptionThesis (Medical)--Bezmialem Vakıf University, Faculty of Medicine, Department of Internal Medicine, Istanbul, 2017en
dc.description.abstractIntroduction-Purpose: It is important that the neoadjuvant chemotherapy response of locally advanced breast cancer patients can be predicted. Apoptotic marker M30 and apoptotic and necrosis marker M65 levels, which are cytoskeletal elements of cytokeratin 18 , reflects tumor cell activity by epithelial cancer patients. The aim of our study is to investigate the relation and prognostic value of M30, M65 and M65-30 (Necrosis) levels with prognostic criteria in neoadjuvant treatment of breast cancer. Materials and Methods: Fourty-one patients with a mean age of 46.2 (28-67) with breast cancer who underwent neoadjuvant chemotherapy were included to this prospective study. Patients received paclitaxel treatment for 12 weeks following chemotherapy with the first 4 cycles of anthracycline (FEC, AC or EC). Blood samples were collected before treatment (0) and 21 days after the 2nd, 4th, and 8th cycles. M30 and M65 levels were measured by ELISA. Findings: The increase in M30 and M65 levels were significant between cycles (p <0.05), but no significant correlation was found in the distribution of M65-30. There was a significant increase in M30 and M65 in first four cycles, and a decrease in 8th cycle was observed. M30, M65 and M65-30 levels were compared with ER, PR, c-Erb-2, Ki-67, pathological-T, pathologic-N and chemotherapy responses and only significant correlation (P = 0.04) was found between M65 and pathologic-N. Conclusion: In our study, M30 and M65 levels were significantly increased in first four cycles, when patients received anthracycline-containing chemotherapy and significantly decreased after paclitaxel chemotherapy, so after 8th cycle. There were no relationship between ER, PR, c-Erb-2, Ki-67, pathologic-T, pathologic-N and treatment response. More extensive studies are needed to assess the predictive and prognostic value of M30 and M65. Key words: Breast cancer, M30, M65, neoadjuvant chemotherapyen
dc.description.abstract{{abstract}}
dc.identifier.urihttp://hdl.handle.net/20.500.12645/18379
dc.language.isoenen
dc.publisherBezmialem Vakıf Universityen
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.subjectOnkoloji = Oncologytr_TR
dc.titleNeoadjuvan kemoterapi alan meme kanserli hastalarda serum M30 ve M65 düzeylerinin klinik ve patolojik prognostik parametrelerle ilişkisi ve prediktif değeri / Relationship of serum M30 and M65 levels with clinical andpatological prognostic parameters and predictive valuein neoadjuvan chemotherapy of breast cancer patientstr_TR
dc.typeThesisen
dc.typeThesis
dspace.entity.typePublication
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Neoadjuvan kemoterapi alan meme kanserli hastalarda serum M30 ve M65 düzeylerinin klinik ve patolojik prognostik parametrelerle ilişkisi ve prediktif değeri.pdf
Size:
1.28 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.14 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Tıpta Uzmanlık Tezleri